InvestSMART

Dimerix Limited (ASX: DXB) - Announcements

- Current share price for DXB : $0.240

ASX company news and announcements for Dimerix Limited (DXB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Dimerix Limited (DXB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Dimerix Limited (DXB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Dimerix Limited (DXB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$144 Trading Halt 15 Jul 2026 8:42AM $0.240 $0.240 fallen by 0%
$144 DMX-200 Available To Patients Via Post-Trial Access Pathways 9 Jul 2026 8:46AM $0.240 $0.240 fallen by 0%
$144 Dimerix Investor Webinar 16 Jun 2026 10:31AM $0.165 $0.240 risen by 45.45%
$144 Dimerix Licenses DMX200 to Everest for China and Asia Region 16 Jun 2026 10:20AM $0.165 $0.240 risen by 45.45%
$144 Trading Halt 15 Jun 2026 9:13AM $0.165 $0.240 risen by 45.45%
$144 Dimerix Quarterly Activities Report and Appendix 4C 30 Apr 2026 9:13AM $0.215 $0.240 risen by 11.63%
$144 Dimerix Releases Investor Presentation and Video Recording 28 Apr 2026 10:26AM $0.235 $0.240 risen by 2.13%
$144 ACTION3 Statistical Review Complete 28 Apr 2026 9:20AM $0.390 $0.240 fallen by 38.46%
$144 Dimerix Singapore Investor Briefing 9 Apr 2026 2:01PM $0.350 $0.240 fallen by 31.43%
$144 Dimerix Presents at Euroz Hartleys Institutional Conference 16 Mar 2026 9:20AM $0.350 $0.240 fallen by 31.43%
$144 Dimerix to Conduct Review of ACTION3 Statistical Assumptions 16 Mar 2026 8:29AM $0.350 $0.240 fallen by 31.43%
$144 Dimerix Phase 3 Trial Last Patient Receives First Dose 10 Mar 2026 9:21AM $0.375 $0.240 fallen by 36%
$144 Dimerix Invitation to Perth and Singapore Investor Briefings 4 Mar 2026 9:38AM $0.410 $0.240 fallen by 41.46%
$144 Dimerix Presents at Oppenheimer Life Sciences Conference 27 Feb 2026 9:23AM $0.455 $0.240 fallen by 47.25%
$144 Appendix 4D and Half Year Financial Report 26 Feb 2026 9:30AM $0.440 $0.240 fallen by 45.45%
$144 Dimerix to Present at Euroz Hartleys Healthcare Forum 2026 5 Feb 2026 9:26AM $0.525 $0.240 fallen by 54.29%
$144 Quarterly Appendix 4C and Activities Report 29 Jan 2026 9:39AM $0.525 $0.240 fallen by 54.29%
$144 Appointment of CFO/Company Secretary 21 Jan 2026 8:28AM $0.520 $0.240 fallen by 53.85%
$144 Clinical trial update at J.P. Morgan Healthcare Conference 12 Jan 2026 8:28AM $0.540 $0.240 fallen by 55.56%
$144 Dimerix receives input from FDA on ACTION3 trial endpoints 24 Dec 2025 8:36AM $0.625 $0.240 fallen by 61.60%
$144 BioMarin to acquire Dimerix US Partner, Amicus Therapeutics 22 Dec 2025 9:16AM $0.560 $0.240 fallen by 57.14%
$144 DMX-200 ACTION3 Phase 3 Trial Completes Recruitment 15 Dec 2025 8:45AM $0.600 $0.240 fallen by 60%
$144 Change of Director's Interest Notice - CS,HA,NW,SP & MD 12 Dec 2025 2:50PM $0.598 $0.240 fallen by 59.83%
$144 Notification regarding unquoted securities - DXB 12 Dec 2025 2:04PM $0.600 $0.240 fallen by 60%
$144 Successful Completion of Planned IDMC Review 19 Nov 2025 9:05AM $0.460 $0.240 fallen by 47.83%

1 - 25 of 716 results

Page 1 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.